MPAA

Business Context and Reporting Period

Company: Motorcar Parts of America, Inc. (MPAA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2025 (Third Quarter of Fiscal Year 2026)
Business Overview: A leading supplier of automotive aftermarket non-discretionary replacement parts (alternators, starters, brakes, wheel hubs) and test solutions/diagnostic equipment. The company operates primarily in North America with significant manufacturing and distribution facilities in Mexico and Canada.

Key Financial Metrics

Material Changes vs. Prior Comparable Period

• Revenue Decline (Q3): Net sales decreased 9.9% to $167.7 million compared to $186.2 million in Q3 2024, primarily due to lower purchases by one of the company's largest customers.
• Revenue Growth (9mo): Net sales increased 2.4% to $577.5 million compared to $564.2 million in the prior year period, aided by the recognition of $14.8 million in remanufactured core revenue from inventory realignment.
• Margin Compression: Gross margin decreased to 19.6% in Q3 (from 24.1% prior year) and 19.0% for the nine months (from 20.4% prior year). Factors included lower sales volume, amortization of core premiums, and $2.1 million in net tariff costs.
• Operating Income Volatility: Operating income dropped 52.6% in Q3 to $8.3 million but increased 89.3% for the nine months to $44.8 million. The nine-month increase was significantly driven by a $10.4 million non-cash foreign exchange gain on lease liabilities, compared to an $18.9 million loss in the prior year.
• Interest Expense Reduction: Interest expense decreased 24.5% in Q3 and 15.3% for the nine months, attributed to lower utilization of accounts receivable discount programs and lower average outstanding balances on the credit facility.

Guidance, Outlook, and Risks

• Capital Allocation: The Board increased the share repurchase program authorization to $57.0 million. As of December 31, 2025, $25.1 million remains available. The company repurchased 669,472 shares for $8.4 million during the nine-month period.
• Liquidity: Management believes cash, receivable discount programs, and the credit facility ($128.6 million available) are sufficient for the next 12 months. The company is not required to test the fixed charge coverage ratio covenant as undrawn availability exceeds the 22.5% threshold.
• Convertible Notes: The company holds $38.7 million in principal of convertible notes due in 2029 with an effective interest rate of 18.3%. These notes contain a compound net derivative liability which resulted in a $3.9 million non-cash gain in Q3.
• Customer Concentration: Three customers accounted for approximately 85% of net sales in Q3 2025 (Customer A: 49%, Customer B: 20%, Customer C: 16%).
• Inventory Realignment: The company reduced the carrying value of remanufactured cores held at customer locations by $14.2 million during the nine months ended December 31, 2025, due to inventory realignment at certain distribution centers.
• Regulatory/Tax: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025, though it did not have a material impact for the current fiscal year.

Investor Verification Checklist

• Customer Concentration Risk: Verify the stability of the top three customers, particularly Customer A (49% of Q3 sales), given the recent sales decline attributed to lower purchases by a major customer.
• Foreign Exchange Impact: Assess the sustainability of operating income, noting that the nine-month increase was heavily influenced by a $10.4 million non-cash FX gain on lease liabilities, which is volatile.
• Inventory Valuation: Review the $14.2 million write-down of cores held at customer locations and the ongoing revaluation of contract assets to ensure inventory levels align with demand.
• Debt Structure: Analyze the impact of the high effective interest rate (18.3%) on the convertible notes and the potential dilution if conversion occurs.
• Tariff Exposure: Confirm the extent of future tariff costs, as $2.1 million in net tariff costs impacted gross margin in the first nine months.